🇺🇸 FDA
Pipeline program

ORY-2001 Low dose

CL05-ORY-2001US

Phase 2 small_molecule completed

Quick answer

ORY-2001 Low dose for Mild to Moderate Alzheimer's Disease is a Phase 2 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Mild to Moderate Alzheimer's Disease
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials